Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies.
Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies.
复制标题
DOI：
10.1016/j.neulet.2016.11.064
复制
发表时间：
2017-05-10
影响因子：
2.5
通讯作者：
Abdallah CG
中科院分区：
文献类型：
--
作者：
Averill LA;Purohit P;Averill CL;Boesl MA;Krystal JH;Abdallah CG
创伤后应激障碍（PTSD）是一种慢性和衰弱的精神疾病，困扰着世界各地数百万人。虽然缺乏强有力的药物干预措施，但我们对PTSD的神经生物学基础的理解在过去二十年中显着增加。越来越多的证据表明，情绪，焦虑和创伤相关疾病和谷氨酸神经传递功能障碍的异常谷氨酸能功能越来越多地被认为是包括PTSD在内的应激相关精神疾病的主要特征。作为PTSD特刊的一部分，这篇小型综述简要讨论了（1）PTSD中谷氨酸能异常的证据，重点是人类受试者的数据;（2）谷氨酸调节剂作为PTSD的潜在替代药物治疗;（3）文献中的选定空白和相关的未来方向。
Posttraumatic stress disorder (PTSD) is a chronic and debilitating psychiatric disorder afflicting millions of individuals across the world. While the availability of robust pharmacologic interventions is quite lacking, our understanding of the putative neurobiological underpinnings of PTSD has significantly increased over the past two decades. Accumulating evidence demonstrates aberrant glutamatergic function in mood, anxiety, and trauma-related disorders and dysfunction in glutamate neurotransmission is increasingly considered a cardinal feature of stress-related psychiatric disorders including PTSD. As part of a PTSD Special Issue, this mini-review provides a concise discussion of (1) evidence of glutamatergic abnormalities in PTSD, with emphasis on human subjects data; (2) glutamate-modulating agents as potential alternative pharmacologic treatments for PTSD; and (3) selected gaps in the literature and related future directions.